Flexion Therapeutics Inc (NASDAQ:FLXN) CFO David Arkowitz purchased 4,000 shares of the business’s stock in a transaction dated Monday, May 13th. The stock was bought at an average cost of $11.99 per share, for a total transaction of $47,960.00. Following the purchase, the chief financial officer now owns 86,924 shares in the company, valued at $1,042,218.76. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
David Arkowitz also recently made the following trade(s):
- On Wednesday, May 8th, David Arkowitz sold 2,248 shares of Flexion Therapeutics stock. The shares were sold at an average price of $10.06, for a total value of $22,614.88.
Flexion Therapeutics stock traded down $0.18 during mid-day trading on Friday, hitting $13.08. 4,914 shares of the company’s stock were exchanged, compared to its average volume of 599,443. The company has a market capitalization of $493.11 million, a PE ratio of -2.90 and a beta of 1.56. Flexion Therapeutics Inc has a fifty-two week low of $9.65 and a fifty-two week high of $29.10. The company has a current ratio of 6.32, a quick ratio of 6.06 and a debt-to-equity ratio of 2.10.
Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.13) by $0.04. The firm had revenue of $10.56 million during the quarter, compared to analysts’ expectations of $11.10 million. Flexion Therapeutics had a negative return on equity of 131.94% and a negative net margin of 549.07%. Analysts predict that Flexion Therapeutics Inc will post -4.07 EPS for the current fiscal year.
Several brokerages recently commented on FLXN. BidaskClub downgraded Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, March 7th. Benchmark raised Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective on the stock in a research note on Thursday, May 9th. Laidlaw set a $18.00 price objective on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Thursday, April 11th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 6th. Finally, Northland Securities reaffirmed a “buy” rating and set a $20.00 price objective on shares of Flexion Therapeutics in a research note on Friday, March 1st. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the stock. Flexion Therapeutics currently has an average rating of “Buy” and an average target price of $23.71.
Hedge funds have recently added to or reduced their stakes in the business. Carroll Financial Associates Inc. increased its holdings in Flexion Therapeutics by 100.0% during the 4th quarter. Carroll Financial Associates Inc. now owns 2,000 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 1,000 shares in the last quarter. Next Capital Management LLC bought a new position in Flexion Therapeutics during the 4th quarter worth about $84,000. BNP Paribas Arbitrage SA grew its holdings in shares of Flexion Therapeutics by 53,692.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 6,980 shares in the last quarter. Advisor Group Inc. grew its holdings in shares of Flexion Therapeutics by 68.2% in the 4th quarter. Advisor Group Inc. now owns 8,608 shares of the specialty pharmaceutical company’s stock valued at $97,000 after acquiring an additional 3,490 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY grew its holdings in shares of Flexion Therapeutics by 341.0% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,455 shares of the specialty pharmaceutical company’s stock valued at $118,000 after acquiring an additional 8,084 shares in the last quarter. Hedge funds and other institutional investors own 94.96% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Macon Daily and is the sole property of of Macon Daily. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://macondaily.com/2019/05/17/insider-buying-flexion-therapeutics-inc-flxn-cfo-buys-4000-shares-of-stock.html.
About Flexion Therapeutics
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Featured Story: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.